-
1
-
-
84894198937
-
-
WHO, Geneva. WHO/HTM/TB/2014.08. Available at
-
World Health Organization (2014) Global tuberculosis report 2014. WHO, Geneva. WHO/HTM/TB/2014.08. Available at http://www.who.int/tb/publications/global-report/en/.
-
(2014)
Global Tuberculosis Report 2014
-
-
-
2
-
-
0027446941
-
Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months
-
letter PMID: 8466107
-
Mitchison DA (1993) Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months [letter]. Am Rev Respir Dis 147: 1062-1063. PMID: 8466107
-
(1993)
Am Rev Respir Dis
, vol.147
, pp. 1062-1063
-
-
Mitchison, D.A.1
-
3
-
-
74549209135
-
Biomarkers for tuberculosis disease activity, cure, and relapse
-
PMID: 20113972
-
Wallis RS, Wang C, Doherty TM, Onyebujoh P, Vahedi M, Laang H et al. (2010) Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis 10: 68-69. doi: 10.1016/S1473-3099(10)70003-7 PMID: 20113972
-
(2010)
Lancet Infect Dis
, vol.10
, pp. 68-69
-
-
Wallis, R.S.1
Wang, C.2
Doherty, T.M.3
Onyebujoh, P.4
Vahedi, M.5
Laang, H.6
-
4
-
-
84877309715
-
An Evaluation of Culture Results during Treatment for Tuberculosis as Surrogate Endpoints for Treatment Failure and Relapse
-
PMID: 23667677
-
Phillips PP, Fielding K, Nunn AJ (2013) An Evaluation of Culture Results during Treatment for Tuberculosis as Surrogate Endpoints for Treatment Failure and Relapse. PLoS One 8: e63840. doi: 10.1371/journal.pone.0063840 PMID: 23667677
-
(2013)
PLoS One
, vol.8
, pp. e63840
-
-
Phillips, P.P.1
Fielding, K.2
Nunn, A.J.3
-
5
-
-
84881114100
-
Month 2 culture status and treatment duration as predictors of tuberculosis relapse risk in a meta-regression model
-
PMID: 23940699
-
Wallis RS, Wang C, Meyer D, Thomas N (2013) Month 2 culture status and treatment duration as predictors of tuberculosis relapse risk in a meta-regression model. PLoS ONE 8: e71116. doi: 10.1371/journal.pone.0071116 PMID: 23940699
-
(2013)
PLoS ONE
, vol.8
, pp. e71116
-
-
Wallis, R.S.1
Wang, C.2
Meyer, D.3
Thomas, N.4
-
6
-
-
84908126151
-
Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis
-
PMID: 25196020
-
Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR et al. (2014) Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis. N Engl J Med 371: 1577-1587. doi: 10.1056/NEJMoa1407426 PMID: 25196020
-
(2014)
N Engl J Med
, vol.371
, pp. 1577-1587
-
-
Gillespie, S.H.1
Crook, A.M.2
McHugh, T.D.3
Mendel, C.M.4
Meredith, S.K.5
Murray, S.R.6
-
7
-
-
84908147456
-
A Four-Month Gatifloxacin-Containing Regimen for Treating Tuberculosis
-
PMID: 25337748
-
Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T et al. (2014) A Four-Month Gatifloxacin-Containing Regimen for Treating Tuberculosis. N Engl J Med 371: 1588-1598. doi: 10.1056/NEJMoa1315817 PMID: 25337748
-
(2014)
N Engl J Med
, vol.371
, pp. 1588-1598
-
-
Merle, C.S.1
Fielding, K.2
Sow, O.B.3
Gninafon, M.4
Lo, M.B.5
Mthiyane, T.6
-
8
-
-
84908139920
-
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis
-
PMID: 25337749
-
Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S et al. (2014) High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 371: 1599-1608. doi: 10.1056/NEJMoa1314210 PMID: 25337749
-
(2014)
N Engl J Med
, vol.371
, pp. 1599-1608
-
-
Jindani, A.1
Harrison, T.S.2
Nunn, A.J.3
Phillips, P.P.4
Churchyard, G.J.5
Charalambous, S.6
-
9
-
-
69949099207
-
Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion
-
PMID: 19542476
-
Johnson JL, Hadad DJ, Dietze R, Noia Maciel EL, Sewali B, Gitta P et al. (2009) Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med 180: 558-563. doi: 10.1164/rccm.200904-0536OC PMID: 19542476
-
(2009)
Am J Respir Crit Care Med
, vol.180
, pp. 558-563
-
-
Johnson, J.L.1
Hadad, D.J.2
Dietze, R.3
Noia Maciel, E.L.4
Sewali, B.5
Gitta, P.6
-
12
-
-
76149124232
-
Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis
-
PMID: 20003697
-
Wang JY, Wang JT, Tsai TH, Hsu CL, Yu CJ, Hsueh PR et al. (2010) Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis. Int J Tuberc Lung Dis 14: 65-71. PMID: 20003697
-
(2010)
Int J Tuberc Lung Dis
, vol.14
, pp. 65-71
-
-
Wang, J.Y.1
Wang, J.T.2
Tsai, T.H.3
Hsu, C.L.4
Yu, C.J.5
Hsueh, P.R.6
-
13
-
-
67749086328
-
Substitution of Moxifloxacin for Isoniazid During Intensive Phase Treatment of Pulmonary Tuberculosis
-
PMID: 19406981
-
Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L et al. (2009) Substitution of Moxifloxacin for Isoniazid During Intensive Phase Treatment of Pulmonary Tuberculosis. Am J Respir Crit Care Med 180: 273-80. doi: 10.1164/rccm.200901-0078OC PMID: 19406981
-
(2009)
Am J Respir Crit Care Med
, vol.180
, pp. 273-280
-
-
Dorman, S.E.1
Johnson, J.L.2
Goldberg, S.3
Muzanye, G.4
Padayatchi, N.5
Bozeman, L.6
-
14
-
-
63349091494
-
Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: A double-blind, randomised, controlled phase II trial
-
PMID: 19345831
-
Conde MB, Efron A, Loredo C, De Souza GR, Graca NP, Cezar MC et al. (2009) Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 373: 1183-1189. doi: 10.1016/S0140-6736(09)60333-0 PMID: 19345831
-
(2009)
Lancet
, vol.373
, pp. 1183-1189
-
-
Conde, M.B.1
Efron, A.2
Loredo, C.3
De Souza, G.R.4
Graca, N.P.5
Cezar, M.C.6
-
15
-
-
38949197081
-
A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis
-
PMID: 18230244
-
Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, Mthiyane T et al. (2008) A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 12: 128-138. PMID: 18230244
-
(2008)
Int J Tuberc Lung Dis
, vol.12
, pp. 128-138
-
-
Rustomjee, R.1
Lienhardt, C.2
Kanyok, T.3
Davies, G.R.4
Levin, J.5
Mthiyane, T.6
-
16
-
-
33746599368
-
Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis
-
PMID: 16675781
-
Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher AW et al. (2006) Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 174: 331-338. PMID: 16675781
-
(2006)
Am J Respir Crit Care Med
, vol.174
, pp. 331-338
-
-
Burman, W.J.1
Goldberg, S.2
Johnson, J.L.3
Muzanye, G.4
Engle, M.5
Mosher, A.W.6
-
17
-
-
0027331616
-
Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection
-
PMID: 7902049
-
Jones BE, Young SMM, Antoniskis D, Davidson PT, Kramer F, Barnes PF (1993) Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis 148: 1292-1297. PMID: 7902049
-
(1993)
Am Rev Respir Dis
, vol.148
, pp. 1292-1297
-
-
Jones, B.E.1
Young, S.M.M.2
Antoniskis, D.3
Davidson, P.T.4
Kramer, F.5
Barnes, P.F.6
-
18
-
-
33144471064
-
Comparison of intermittent ethambutol with rifampicin-based regimens in HIV-infected adults with PTB, Kampala
-
PMID: 16466035
-
Okwera A, Johnson JL, Luzze H, Nsubuga P, Kayanja H, Cohn DL et al. (2006) Comparison of intermittent ethambutol with rifampicin-based regimens in HIV-infected adults with PTB, Kampala. Int J Tuberc Lung Dis 10: 39-44. PMID: 16466035
-
(2006)
Int J Tuberc Lung Dis
, vol.10
, pp. 39-44
-
-
Okwera, A.1
Johnson, J.L.2
Luzze, H.3
Nsubuga, P.4
Kayanja, H.5
Cohn, D.L.6
-
19
-
-
41849150709
-
Pharmacometrics: A multidisciplinary field to facilitate critical thinking in drug development and translational research settings
-
PMID: 18440922
-
Barrett JS, Fossler MJ, Cadieu KD, Gastonguay MR (2008) Pharmacometrics: a multidisciplinary field to facilitate critical thinking in drug development and translational research settings. J Clin Pharmacol 48: 632-649. doi: 10.1177/0091270008315318 PMID: 18440922
-
(2008)
J Clin Pharmacol
, vol.48
, pp. 632-649
-
-
Barrett, J.S.1
Fossler, M.J.2
Cadieu, K.D.3
Gastonguay, M.R.4
|